MinK Therapeutics

Share on: 

AgenTus Therapeutics is using mammalian display platform technologies to discover T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs) to weaponize adoptive cell therapies to treat cancer.

COVID-19; (11/2020) initiated dosing of the first patient for its trial assessing its allogeneic cell therapy agenT-797, developed to treat COVID-19.

Career Page(s): 
Lexington MA
United States
United Kingdom